Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus

References

• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17:253-76; PMID:17579921; http://dx.doi.org/10.1002/rmv.535
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233-9; PMID:15307033; http://dx.doi.org/10.1086/421999
   PubMed Web of Science ®Google Scholar
• Griffiths PD. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis 2012; 12:790-8; PMID:23017365; http://dx.doi.org/10.1016/S1473-3099(12)70197-4
   PubMed Web of Science ®Google Scholar
• Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171:26-32; PMID:7798679; http://dx.doi.org/10.1093/infdis/171.1.26
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, Corey L, Hill J, Davis E, Flanigan C, et al. Vaccine Prevention of Maternal Cytomegalovirus Infection. N Engl J Med 2009; 360:1191-9; PMID:19297572; http://dx.doi.org/10.1056/NEJMoa0804749
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. The Lancet 2011; 377:1256-63; http://dx.doi.org/10.1016/S0140-6736(11)60136-0
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human Cytomegalovirus UL131 Open Reading Frame Is Required for Epithelial Cell Tropism. J Virol 2005; 79:10330-8; PMID:16051825; http://dx.doi.org/10.1128/JVI.79.16.10330-10338.2005
   PubMed Web of Science ®Google Scholar
• Isaacson MK, Compton T. Human Cytomegalovirus Glycoprotein B Is Required for Virus Entry and Cell-to-Cell Spread but Not for Virion Attachment, Assembly, or Egress. J Virol 2009; 83:3891-903; PMID:19193805; http://dx.doi.org/10.1128/JVI.01251-08
   PubMed Web of Science ®Google Scholar
• Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal Structure of Glycoprotein B from Herpes Simplex Virus 1. Science 2006; 313:217-20; PMID:16840698; http://dx.doi.org/10.1126/science.1126548
   PubMed Web of Science ®Google Scholar
• Heldwein EE, Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 2008; 65:1653-68; PMID:18351291; http://dx.doi.org/10.1007/s00018-008-7570-z
   PubMed Web of Science ®Google Scholar
• Stampfer SD, Lou H, Cohen GH, Eisenberg RJ, Heldwein EE. Structural Basis of Local, pH-Dependent Conformational Changes in Glycoprotein B from Herpes Simplex Virus Type 1. J Virol 2010; 84:12924-33; PMID:20943984; http://dx.doi.org/10.1128/JVI.01750-10
   PubMed Web of Science ®Google Scholar
• Lopper M, Compton T. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J Virol 2004; 78:8333-41; PMID:15254205; http://dx.doi.org/10.1128/JVI.78.15.8333-8341.2004
   PubMed Web of Science ®Google Scholar
• Britt WJ. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984; 135:369-78; PMID:6330979; http://dx.doi.org/10.1016/0042-6822(84)90193-4
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85; PMID:16147978; http://dx.doi.org/10.1084/jem.20050882
   PubMed Web of Science ®Google Scholar
• Meyer H, Sundqvist V-A, Pereira L, Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 1992; 73:2375-83; PMID:1383409; http://dx.doi.org/10.1099/0022-1317-73-9-2375
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Sugano T, Miyamoto C, Masuho Y. Generation of hybridomas producing human monoclonal antibodies against human cytomegalovirus. Biochem Biophys Res Commun 1986; 137:273-80; PMID:3013182; http://dx.doi.org/10.1016/0006-291X(86)91206-4
   PubMed Web of Science ®Google Scholar
• Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex. J Virol 2010; 84:1005-13; PMID:19889756; http://dx.doi.org/10.1128/JVI.01809-09
   PubMed Web of Science ®Google Scholar
• Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 1993; 67:703-10; PMID:7678304
   PubMed Web of Science ®Google Scholar
• Reeves MB, Breidenstein A, Compton T. Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci 2012; 109:588-93; PMID:22203987; http://dx.doi.org/10.1073/pnas.1114966108
   PubMed Web of Science ®Google Scholar
• Kauvar LM, Liu K, Park M, DeChene N, Stephenson R, Tenorio E, Ellsworth SL, Tabata T, Petitt M, Tsuge M, et al. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother 2015; 59:1558-68; PMID:25534746; http://dx.doi.org/10.1128/AAC.04295-14
   PubMed Web of Science ®Google Scholar
• Theraclone Sciences, Inc. Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody [Internet]. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01594437
   Google Scholar
• Ohlin M, Silvestri M, Sundqvist VA, Borrebaeck CA. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin Diagn Lab Immunol 1997; 4:107-11; PMID:9008292
   PubMedGoogle Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 2005; 102:18153-8; PMID:16319222; http://dx.doi.org/10.1073/pnas.0509201102
   PubMed Web of Science ®Google Scholar
• Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci 2013; 110:E4997-5005; PMID:24297878; http://dx.doi.org/10.1073/pnas.1316517110
   PubMed Web of Science ®Google Scholar
• Nest GV, Ott G, Barchfeld G. Adjuvant formulation comprising a submicron oil droplet emulsion [Internet]. 2001 [cited 2015 Jul 14]; Available from: http://www.google.com/patents/US6299884
   Google Scholar
• Fu T-M, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009; 27:1440-7; PMID:19146898; http://dx.doi.org/10.1016/j.vaccine.2008.12.034
   PubMed Web of Science ®Google Scholar
• Ohlin M, Söderberg-Nauclér C. Human antibody technology and the development of antibodies against cytomegalovirus. Mol Immunol 2015; 67:153-70; PMID:25802091; http://dx.doi.org/10.1016/j.molimm.2015.02.026; Available from: http://www.sciencedirect.com/science/article/pii/S0161589015000759
   Web of Science ®Google Scholar
• McLean GR, Olsen OA, Watt IN, Rathanaswami P, Leslie KB, Babcook JS, Schrader JW. Recognition of Human Cytomegalovirus by Human Primary Immunoglobulins Identifies an Innate Foundation to an Adaptive Immune Response. J Immunol 2005; 174:4768-78; PMID:15814702; http://dx.doi.org/10.4049/jimmunol.174.8.4768
   PubMed Web of Science ®Google Scholar
• Ohlin M. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign? Mol Immunol 2014; 60:95-102; PMID:24802891; http://dx.doi.org/10.1016/j.molimm.2014.03.015
   PubMed Web of Science ®Google Scholar
• Burke HG, Heldwein EE. Crystal Structure of the Human Cytomegalovirus Glycoprotein B. PLoS Pathog 2015; 11:e1005227; PMID:26484870; http://dx.doi.org/10.1371/journal.ppat.1005227
   PubMed Web of Science ®Google Scholar
• Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, Ingallinella P, McKenna P, Citron M, Ottinger E, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 2010; 107:10655-60; PMID:20483992; http://dx.doi.org/10.1073/pnas.1004261107
   PubMed Web of Science ®Google Scholar
• Shinefield HR. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine 2010; 28:4335-9; PMID:20452430; http://dx.doi.org/10.1016/j.vaccine.2010.04.072
   PubMed Web of Science ®Google Scholar
• Nahas DD, Palladino JS, Joyce JG, Hepler RW. Amino acid analysis of peptide loading ratios in conjugate vaccines: a comparison of direct electrochemical detection and 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate pre-column derivatization methods. Bioconjug Chem 2008; 19:322-6; PMID:18072716; http://dx.doi.org/10.1021/bc700232z
   PubMed Web of Science ®Google Scholar
• Caro-Aguilar I, Ottinger E, Hepler RW, Nahas DD, Wu C, Good MF, Batzloff M, Joyce JG, Heinrichs JH, Skinner JM. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccines Immunother 2013; 9:488-96; http://dx.doi.org/10.4161/hv.23224
   PubMed Web of Science ®Google Scholar
• Spaete RR, Pachl CA. Polynucleotides encoding CMV neutralizing proteins [Internet]. 1998 [cited 2015 Jul 14]; Available from: http://www.google.com/patents/US5834307
   Google Scholar
• Tang A, Li F, Freed DC, Finnefrock AC, Casimiro DR, Wang D, Fu T-M. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 2011; 29:8350-6; PMID:21888937; http://dx.doi.org/10.1016/j.vaccine.2011.08.086
   PubMed Web of Science ®Google Scholar
• Britt WJ. Human cytomegalovirus: propagation, quantification, and storage. Curr Protoc Microbiol 2010; 18:E:14E.3:14E.3.1–14E.3.17; PMID:20812216.
   PubMedGoogle Scholar
• Fu T-M, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 2012; 30:7469-74; PMID:23107592; http://dx.doi.org/10.1016/j.vaccine.2012.10.053
   PubMed Web of Science ®Google Scholar
• Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu T-M. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 2011; 29:9075-80; PMID:21945962; http://dx.doi.org/10.1016/j.vaccine.2011.09.056
   PubMed Web of Science ®Google Scholar